Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOASIS phase II study of glofitamab combinations in high-risk mantle-cell lymphoma
2023-506706-40-00Phase 3Authorised
- Sponsor
- LYSARC
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of glofitamab, venetoclax and zanubrutinib in mantle cell lymphoma (MCL) (3 cohorts), sponsored by LYSARC. Primary endpoint: Progression-free survival at 12 months. Planned start Jul 2024; status: authorised.
02
Drugs
glofitamabvenetoclaxzanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-506706-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506706-40-00.